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Abstract
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and
efﬁcacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the
prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed.
Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed
with a margin of safety of about 4. The FEEDAP Panel assumes that the residues in duck tissues would
be of the same magnitude as those measured in the physiologically similar major species, chickens for
fattening. The use of Monteban® G100 at a maximum concentration of 70 mg/kg complete feed for
ducks for fattening is safe for the consumer without applying a withdrawal period, provided the
maximum residue limit (MRL) of 50 lg narasin/kg for all wet tissues would not be exceeded.
Monteban® G100 is irritant to the eyes but not to the skin. It has the potential to induce skin
sensitisation. The acute systemic toxicity following dermal application is low. Inhalation exposure would
pose a risk to persons handling the additive. Narasin, when used as feed additive for ducks for
fattening at 70 mg/kg feed, is not expected to pose a risk to the environment. The risk for sediment
compartment cannot be assessed. Narasin is not considered to have a bioaccumulation potential.
Insufﬁcient data were provided to allow a conclusion on the efﬁcacy of Monteban® G100 in ducks.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from Eli Lilly and Company Ltd2 for authorisation of
the product Monteban® G100 (narasin), when used as a feed additive for ducks (category:
coccidiostats and histomonostats).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the
applicant the technical dossier in support of this application. The particulars and documents in support
of the application were considered valid by EFSA as of 28 April 2015.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Monteban® G100 (narasin), when used under the proposed conditions of use (see
Section 3.1).
1.2. Additional information
The additive Monteban® G100 is a feed additive intended to be used for the control of coccidiosis
in ducks. It contains, as the active ingredient, the polyether ionophore narasin which is produced by
fermentation of a strain of Streptomyces spp. (NRRL 8092).
Monteban® G100 has never been authorised for use in ducks in the European Union. It has been
authorised for use in chickens for fattening until August 2014 pursuant to Commission Regulation (EC)
No 1464/20043 amended by Commission Regulation (EU) No 884/20104.
EFSA issued an opinion on the safety and efﬁcacy of Monteban® G100 (EFSA, 2004) for chickens
for fattening followed by an opinion on the reduction of the withdrawal time (EFSA FEEDAP Panel,
2010). Recently, Monteban® G100 has been evaluated by the FEEDAP Panel under Article 10(2) of
Regulation (EC) No 1831/2003 (EFSA FEEDAP Panel, 2018).
In 2012, the joint FAO/WHO expert committee on food additives evaluated narasin as a veterinary
drug (JECFA, 2012).
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier5 in support of the authorisation request for the use of Monteban® G100 as a feed additive. The
technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003 and
the applicable EFSA guidance documents.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies, peer-reviewed scientiﬁc papers,
other scientiﬁc reports and experts’ knowledge, to deliver the present output.
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 On 15/06/2018 the applicant informed EFSA that the petitioner changed from Eli Lilly and Company Ltd. to Elanco GmbH,
Heinz-Lohmann-Str. 4. 27472 Cuxhaven, Germany.
3 Commission Regulation (EC) No 1464/2004 of 17 August 2004 concerning the authorisation for 10 years of the additive
‘Monteban’ in feedingstuffs, belonging to the group of coccidiostats and other medicinal substances. OJ L 270, 18.8.2004, p. 8.
4 Commission Regulation (EU) No 884/2010 of 7 October 2010 amending Regulation (EC) No 1464/2004 as regards the
withdrawal time of the additive ‘Monteban’, belonging to the group of coccidiostats and other medicinal substances. OJ L 265,
8.10.2010, p. 4.
5 FEED dossier reference: FAD-2015-0001.
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EFSA has veriﬁed the EURL report as it relates to the methods used for the control of the active
substance in animal feed/marker residue in tissues. The Executive Summary of the EURL report can be
found in Annex A.6
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Monteban®
G100 (narasin) for ducks is in line with the principles laid down in Regulation (EC) No 429/20087 and
the relevant guidance documents: Guidance for the preparation of dossiers for coccidiostats and
histomonostats (EFSA FEEDAP Panel, 2011a), Technical guidance: Tolerance and efﬁcacy studies in
target animals (EFSA FEEDAP Panel, 2011b), Technical Guidance for assessing the safety of feed
additives for the environment (EFSA, 2008a), Guidance for establishing the safety of additives for the
consumer (EFSA FEEDAP Panel, 2012a), Guidance on studies concerning the safety of use of the
additive for users/workers (EFSA FEEDAP Panel, 2012b) and Technical Guidance: Microbial Studies
(EFSA, 2008b).
3. Assessment
The present opinion assesses the safety and efﬁcacy of the coccidiostat Monteban® G100
containing narasin as active principle when used as a feed additive in ducks for fattening.
3.1. Characterisation
The additive Monteban® G100 is a feed additive authorised for the control of coccidiosis in chickens
for fattening. It is intended to be used for the control of coccidiosis caused by Tyzzeria perniciosa and
Eimeria mulardi in ducks.
The characterisation of the additive, the active substance and the producing strain, the
manufacturing process and the technological properties of the additive have been recently reviewed in
detail by the FEEDAP Panel (EFSA FEEDAP Panel, 2018).
The active ingredient is the polyether ionophore narasin which is produced by fermentation of a
strain of Streptomyces spp. (NRRL 8092). Limited data on the taxonomic identiﬁcation of the
production strain were provided. Consequently, the identiﬁcation of strain NRRL 8092 as Streptomyces
aureofaciens is not demonstrated. The FEEDAP Panel cannot conclude on the absence of genetic
determinants for antimicrobial resistance in Streptomyces spp. under assessment.
The ﬁnal additive Monteban® G100 is produced by mixing narasin granulated with 10–25 g mineral
oil, 10–20 g vermiculite (expanded vermiculite magnesium-aluminosilicate mineral) per kg additive and
with rice hulls (the quantity is adjusted to ensure a narasin content of Monteban® G100 within the
limit of speciﬁcation). Monteban® G100 contains by speciﬁcation 95.0–107.5 g narasin activity/kg.
The recommended inclusion level of Monteban® G100 in complete feed for ducks is 60–70 mg
narasin/kg complete feed. Maximum residue limits (MRL) of 50 lg narasin/kg for all tissues and a
withdrawal period of zero day is proposed.
3.2. Safety
3.2.1. Absorption, distribution, metabolism, excretion and residues
The metabolic fate of narasin in rat and chickens for fattening has been recently reviewed by the
FEEDAP Panel (EFSA FEEDAP Panel, 2018). Considering that duck is physiologically similar to chicken,
no speciﬁc studies need to be performed and the conclusions of the metabolism of narasin in chickens
for fattening can be extrapolated to ducks: `(i) The main metabolic pathway of narasin in the chicken
and rat involves oxidative processes leading to the formation of di-, tri- and tetra-hydroxynarasins as
well as keto-narasins. (ii) Unchanged narasin is a minor component (up to 5%) of chicken excreta in
the feed dose range proposed, whereas a great number of metabolites have been identiﬁed. Two
major di-hydroxy and two major tri-hydroxy narasin metabolites represented together about 30% of
the whole narasin related excreted compounds. (iii) Narasin metabolites in tissues and excreta are
6 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/ﬁnirep-FAD-2015-0001-monteban.pdf
7 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
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qualitatively similar. The liver is the target tissue. A great number of narasin metabolites represent
each less than 10% of the whole tissue residues. However, for control purposes skin/fat and narasin
should be retained as practical target tissue and marker residue’.
The FEEDAP Panel noted that the proposed inclusion level in ducks is the same as the one in
chickens for fattening (60–70 mg narasin/kg feed) and that the duration of administration is similar. In
accordance with the FEEDAP Guidance on the Extrapolation of data from major species to minor
species (EFSA, 2008c), no additional residue study is required in ducks and the assessment of
consumer safety can be based on residue studies performed in chickens for fattening.
3.2.2. Safety for the target species
3.2.2.1. Tolerance in ducks for fattening
The tolerance study was made according to Good Clinical Practice, blinded and audited. A total of
360 one-day-old Pekin ducks of both sexes was allotted to ﬁve treatment groups which were fed diets
containing Monteban® G100 at concentrations of 0, 70 (1x the maximum level), 140 (2x), 210 (3x) or
280 (4x) mg narasin/kg complete feed for at least 41 days.8 The intended dietary narasin levels were
analytically conﬁrmed (within a margin of  20%). Group size was six replicates with six males and six
female birds. Feed (starter for the ﬁrst 2 weeks, followed by a grower diet) and water were provided
for ad libitum intake. The analysis of the starter and grower feed showed values of 21.1% and 18.9%
for crude protein, of 1.29% and 1.09% for lysine and of 0.35 and 0.32% for methionine, respectively.
Body weight and feed consumption were determined weekly. At days 41, 42 or 43, four birds (two
male and two female) per treatment were selected for blood sampling (haematology9 and clinical
chemistry10). On the same days, 12 birds (six male and six female, one from each pen) per treatment
group were necropsied.
Statistical evaluation was done by analysis of variance (ANOVA). The pen was considered the
statistical unit. Pairwise comparisons of the treated groups with control were conducted using
Dunnett’s test; differences were considered signiﬁcant at a level of p < 0.05 (two-sided).
Ten birds died/were euthanised during the course of the study (seven of them in the control group).
At the end of the study (day 41), no signiﬁcant differences between the groups were observed for
body weight gain, feed consumption and feed to gain ratio. Mean values for females and males were
2,592 and 2,769 g for body weight gain, and 2.73 and 2.63 for feed to gain ratio, respectively.
The individual comparisons showed three signiﬁcant differences to the control group: higher
albumin and calcium concentrations of the use level group in males but not in females (not dose-
related). For inorganic phosphate, there was a linear increase trend in females only, resulting in a
signiﬁcant difference of the 280 mg narasin/kg group (4x) from the control group. For males, a
signiﬁcant linear trend was found for leukocytes. Sodium was not analysed. In summary, there were
no clinically relevant differences in the haematology and blood biochemistry between the control and
the use level groups.
There was no difference in clinical observations. Necropsies did not reveal any difference in type
and frequency of observed lesions between the treatment groups.
3.2.2.2. Interactions
Interactions between the ionophore narasin and other drugs have been recently reviewed by the
FEEDAP Panel (EFSA FEEDAP Panel, 2018). The same conclusions can be applied to the use of
Monteban® G100 in ducks, i.e. ‘the simultaneous use of Monteban® G100 and certain antibiotic drugs
(e.g. tiamulin) is contra-indicated’.
3.2.2.3. Microbial studies
The antimicrobial activity of narasin, as for other ionophoric compounds, is limited to Gram-positive
bacteria. In a recent opinion on the same product (EFSA FEEDAP Panel, 2018), based on a literature
review provided by the applicant, the Panel concluded that ‘The use of narasin as feed additive is
unlikely to induce resistance or cross-resistance to antimicrobials used in human and animal therapy.
8 Technical dossier/Supplementray information June 2017/Annex 40.
9 Red blood cell count, haemoglobin, mean corpuscular haemoglobin concentration, packed cell volume, white blood cell count,
blood differential test, platelet comments and cellular morphology.
10 Aspartate amino transferase, bile acid, protein (total), albumin, uric acid, creatine kinase, lactate dehydrogenase, phosphate,
calcium, potassium, cholinesterase.
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Narasin may increase Salmonella-shedding, but there is no reason to believe that narasin is different
from other polyether ionophores in this respect’.
3.2.2.2. Conclusions on the safety for the target species
The highest applied use level 70 mg narasin from Monteban® G100/kg complete feed did not cause
any adverse effects and is therefore considered safe for ducks for fattening with a margin of safety of
about four.
The simultaneous use of Monteban® G100 and certain antibiotic drugs (e.g. tiamulin) is
contraindicated.
Narasin is active against Gram-positive bacteria, while Gram-negative bacteria are resistant. The
use of narasin as a feed additive is unlikely to induce resistance or cross-resistance to antimicrobials
used in human and animal therapy. Narasin may increase Salmonella-shedding, but there is no reason
to believe that narasin is different from other polyether ionophores in this respect. The simultaneous
use of Monteban® G100 and certain antibiotic drugs (e.g. tiamulin) is contraindicated.
3.2.3. Safety for the consumer
3.2.3.1. Toxicological studies
In its recent opinion on the safety and efﬁcacy of Monteban® G100 for chickens for fattening (EFSA
FEEDAP Panel, 2018), the FEEDAP Panel re-assessed the toxicological studies available for narasin,
submitted also in the current application, and concluded that: ‘Narasin is not genotoxic. No indication
of carcinogenicity or developmental toxicity was found at the doses tested in the mouse, rat and
rabbit. The lowest no observed effect level (NOEL) identiﬁed in the oral toxicity studies was 0.5 mg/kg
bw per day for the neuropathy seen in a one-year dog study. Since this dose is above the lowest
NOAEL previously identiﬁed of 0.5 mg/kg bw per day, there is no reason to consider acute
cardiovascular effects in the risk assessment. The no observed adverse effect level (NOAEL) of 0.5 mg/
kg bw per day is an appropriate base for conﬁrming the acceptable daily intake (ADI) of 0.005 mg
narasin/kg bw already established by the FEEDAP Panel in its former opinions applying a uncertainty
factor of 100’.
3.2.3.2. Assessment of consumer safety
The FEEDAP Panel already assessed the safety of the consumer exposed to narasin residues from
chicken tissues and concluded that the use of Monteban® G100 in chickens for fattening at the
maximum dose proposed, and without applying a withdrawal period, is safe for the consumer (EFSA
FEEDAP Panel, 2010, 2018). Exposure of adults to total narasin residues from edible chicken tissues
would not exceed 20% of the ADI based on the conventional food basket of Regulation (EC) no 429/
2008. Maximum residue limits (MRL) of 50 lg narasin/kg for all wet tissues ensure consumer safety,
MRL-derived residues would account for 58% of the ADI. Applying European food consumption data
from EFSA’s Comprehensive European Food Consumption Database (see Guidance on the assessment
of the safety of feed additives for the consumer (EFSA FEEDAP Panel, 2017)), both values would
decrease to 2% and 20%, respectively. All exposure levels indicate a large margin of safety for adults
consuming chicken tissues.
Since metabolic proximity between the major species chicken and the minor species duck is
considered to be given, no additional residue studies are required for a minor species when the
application level and duration are similar. Assuming that the residues in duck tissues would be of the
same magnitude as those measured in the physiologically similar major species (see Section 3.2.2.1),
the above conclusions apply to the use of Monteban® G100 in the duck. This includes that no
withdrawal time is necessary and that the MRLs established from studies with chickens is taken for
ducks. Considering the large margin of safety established for adults consuming tissues from treated
chicken, the extrapolations made from chicken to duck have a very low level of uncertainties.
3.2.3.3. Conclusion on safety for the consumer
The FEEDAP Panel concludes that the use of Monteban® G100 at a maximum concentration of
70 mg/kg complete feed for ducks for fattening is safe for the consumer. A withdrawal period is not
necessary and the same MRL of 50 lg narasin/kg for all wet tissues as established for chickens applies
to duck tissues.
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3.2.4. Safety for the user
As the product is identical to the one recently re-evaluated by the FEEDAP Panel (EFSA FEEDAP
Panel, 2018), the same conclusions can be reiterated: ‘Monteban® G100 is irritant to the eyes but not
to the skin. It has the potential to induce skin sensitisation. The acute systemic toxicity following
dermal application is low. Inhalation exposure would pose a risk to persons handling the additive’.
3.2.5. Safety for the environment
In accordance with the Technical guidance on the extrapolation from major species to minor
species regarding the assessment of feed additives for use in animal nutrition (EFSA, 2008c), the
environmental risk assessment for ducks can be extrapolated from the assessment done for the use of
narasin in the major species. Recently (EFSA FEEDAP Panel, 2018), the FEEDAP Panel concluded that:
‘Narasin, when used as feed additive for chickens for fattening at 70 mg/kg feed, is not expected to
pose a risk to the environment. The risk for sediment compartment cannot be assessed. Narasin is not
considered to have a bioaccumulation potential’.
As the conditions of use among poultry species are similar, the same conclusion applies to the use
of the additive in ducks.11
3.3. Efﬁcacy
The applicant submitted one ﬂoor pen study in ducks and three ﬂoor pen studies and three
anticoccidial sensitivity tests (AST) in chickens for fattening.
3.3.1. Floor pen study in ducks
For a coccidiostat already approved in a major species, only one study in a minor species is
necessary to conclude on efﬁcacy.
The ﬂoor pen study in ducks for fattening was performed in 2014.12 Ninety-six 1-day-old Peking
ducks were randomly allocated to an uninfected untreated control (UUC) group, an infected untreated
control (IUC) group and an infected treated (IT) group receiving 60 mg narasin/kg feed (analysed
44.8–66.6 mg narasin/kg feed). Group size was four pens with eight animals per pen. The duration of
the trial was 56 days. On day 14, all birds in the IUC and IT groups were inoculated by individual oral
gavage with 61,372 oocysts of a recent ﬁeld isolate of duck coccidia. This inoculum containing Eimeria
anatis, Tyzzeria perniocosa and Wenyonella spp. had been shown in a pilot virulence test to yield mild
to moderate signs of coccidiosis following artiﬁcial challenge with approximately 75,000 sporulated
oocysts. Body weight and feed consumption were measured for the ﬁrst 4 week at weekly intervals
followed by biweekly measurements until the end of the study. Feed to gain ratios were calculated for
the corresponding intervals. Statistical analysis of the zootechnical data was done by comparing the
infected groups with UUC and the treated groups (IT) with the IUC by parametric testing (in case
assumptions are fulﬁlled, method not mentioned) or non-parametric testing (Wilcoxon Mann-Whitney U
test). The statistical tests were two-sided with a 5% signiﬁcance level.
There was no coccidiosis-related mortality in the study. All the bird losses from day 1 to 28 were
related to adenovirus.13 In the period of days 15–28, a total of 14 ducks were found dead or were
euthanised because of illness (in the UUC, IUC and IT groups, 3, 8 and 3 ducks, respectively). Total
losses were three in the UUC group, nine in the IUC group and four in the IT group. Any statistical
outcome of mortality testing is not relevant since only coccidiosis mortality would count for efﬁcacy.
Oocyst excretion and faecal litter scores were measured and clinical observations were recorded.
For these endpoints, which are relevant in the assessment of coccidiostatic activity, no statistical
analysis was provided.
11 The FEEDAP Panel is aware of the fact that under certain husbandry conditions of ducks (i.e. lakes, ponds and rivers), narasin
and its metabolites from droppings can be directly released to surface water.
12 Technical dossier/Section IV/Annex 14.
13 To aid a potential effect of Eimeria inoculation, an immunosuppressant substance (betamethasone) was administered via
water for drinking to all birds from days 13–17. This may have also promoted the severity of an adenovirus infection.
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Mean faecal oocyst counts in the IT narasin group (OPG: 625) were lower compared to the IUC
group (OPG: 30,438) on day 19. In the UUC, no oocyst were found throughout the study. On day 35,
no oocysts were found in all groups.
The faecal litter score value14 in the IT narasin group (1.75/1.0/1.0) was lower than in the IUC
group (2.5/2.0/1.25) on days 20, 21 and 22. The faecal litter score value in the UUC group was 1.0
throughout the days of assessment.
The daily weight gain in the week (days 13–21) after artiﬁcial infection was 29.2 g/duck in the UUC
group, 22.9 g in the IUC (signiﬁcant depression), 28.6 g in the IT group. The ﬁnal body weight was
not signiﬁcantly different between groups (UUC 4,020 g, IUC 3,920 g, IT 4,060 g). The feed to gain
ratio was not signiﬁcantly different between IT (4.98) and IUC group (5.42) in the critical period days
13–21 and over the total period days 1–56 (2.61; 2.85). The feed to gain ratio of the UUC group was
4.57 for the period days 13–21 and 2.68 for days 1–56.
Faecal oocyst counts and faecal litter scores indicate the effect of inoculation resulting in clinical
coccidiosis. The infection was weak, clinical signs disappeared a few weeks after infection. Oocyst
excretion was clearly suppressed by narasin as faecal score was improved compared to the infected
untreated control, however, not statistically analysed. These effects are in line with the better, although
not signiﬁcant (p < 0.08), body weight gain of the treated ducks in the period immediately after
inoculation.
The study shows several weaknesses in conduct and reporting: (i) the inoculum was of low
pathogenicity so that an immunosuppressive drug (betamethasone) had to be administered via water
for drinking for 4 days after infection, (ii) the relevant endpoints (oocyst excretion and faecal litter
scores) were not statistically evaluated, and (iii) the statistical output is mainly limited to tables without
any text explanation.
Based on the data above, Monteban® G100 has not been proven to be efﬁcacious in controlling
coccidiosis in ducks.
3.3.2. Floor pen study in chickens for fattening
The studies in chickens for fattening were described and assessed in a recent opinion of the
FEEDAP Panel (EFSA FEEDAP Panel, 2018). It was concluded that ‘The efﬁcacy of Monteban® G100
was demonstrated in three ﬂoor pen studies and in two ASTs, a third AST lacking to show anticoccidial
efﬁcacy. The FEEDAP Panel is therefore not in a position to conclude on the efﬁcacy of Monteban®
G100 at the minimum applied dose of 60 mg narasin/kg complete feed for chickens for fattening’.
3.3.3. Conclusions on efﬁcacy
The FEEDAP Panel is not in the position to conclude on the efﬁcacy of Monteban® G100 in
controlling coccidiosis in ducks for fattening because the efﬁcacy was not demonstrated neither in the
major species (chickens for fattening) nor in the minor species (ducks).
3.3.4. Post-market monitoring
Field monitoring of Eimeria spp. resistance to narasin should be undertaken, preferably during the
latter part of the period of authorisation.
4. Conclusions
Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed
with a margin of safety of about four. The simultaneous use of Monteban® G100 and certain antibiotic
drugs (e.g. tiamulin) is contraindicated.
The ADME of narasin is considered to be similar in the duck and chicken, two physiologically similar
species. The FEEDAP Panel assumes that the residues in duck tissues would be of the same magnitude
as those measured in chicken tissues. The FEEDAP Panel concludes that the use of Monteban® G100
at a maximum concentration of 70 mg/kg complete feed for ducks for fattening is safe for the
consumer. For ducks a withdrawal period is not necessary and the same MRL of 50 lg narasin/kg for
all wet tissues as established for chickens applies to duck tissues.
14 Faecal aspect within each pen was assessed and given a score based on consistency as follows: Score 1 = Normal; Score 2 =
Any in pen showing mucous consistency, faeces still well formed; Score 3 = All showing mucous consistency, some well
formed, some runny; Score 4 = All showing runny mucous consistency.
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Monteban® G100 is irritant to the eyes but not to the skin. It has the potential to induce skin
sensitisation. The acute systemic toxicity following dermal application is low. Inhalation exposure would
pose a risk to persons handling the additive.
Narasin, when used as a feed additive for ducks for fattening at 70 mg/kg feed, is not expected to
pose a risk to the environment. The risk for sediment compartment cannot be assessed. Narasin is not
considered to have a bioaccumulation potential.
Insufﬁcient data were provided to allow a conclusion on the efﬁcacy of Monteban® G100 in ducks.
5. Recommendations
Narasin is toxic to horses, turkeys and rabbits at levels below those used in the prevention of
coccidiosis in chickens.
Documentation provided to EFSA
1) Monteban® G100 for ducks. January 2015. Submitted by Eli Lilly and Company Ltd.
2) Monteban® G100 for ducks. Supplementary information. October 2015. Submitted by Eli Lilly
and Company Ltd. (not complete)
3) Monteban® G100 for ducks. Supplementary information. June 2017. Submitted by Eli Lilly
and Company Ltd.
4) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods of Analysis for Monteban® G100.
5) Comments from Member States.
Chronology
Date Event
7/1/2015 Dossier received by EFSA
13/1/2015 Reception mandate from the European Commission
28/4/2015 Application validated by EFSA – Start of the scientiﬁc assessment
8/6/2015 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: Evaluation method
25/6/2015 Request of additional supplementary information to the applicant in line with Article 8(1)(2) of
Regulation (EC) No 1831/2003. Issues: Characterisation
17/5/2014 Comments received from Member States
27/10/2015 Reception of supplementary information from the applicant - The information was considered not
complete. Applicant was informed via email dated 30/11/2015. The scientiﬁc assessment remained
suspended
17/5/2016 Request of additional supplementary information to the applicant in line with Article 8(1)(2) of
Regulation (EC) No 1831/2003. Issues: Safety for the target species, Safety for the environment
19/1/2016 Reception of the Evaluation report of the European Union Reference Laboratory for Feed Additives
28/6/2017 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
3/10/2018 Opinion adopted by the FEEDAP Panel. End of the Scientiﬁc assessment
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Abbreviations
ADI acceptable daily intake
ADME absorption, distribution, metabolism and excretion
AST anticoccidial sensitivity tests
bw body weight
EURL European Union Reference Laboratory
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
LOQ limit of quantiﬁcation
MRL maximum residue limit
NOAEL no observed adverse effect level
NOEL no observed effect level
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Methods of Analysis
for Monteban® G100
Monteban® G100 is a feed additive currently authorised for chickens for fattening by Commission
Regulation (EC) No 1464/2004 belonging to the group ‘Coccidiostats and other medicinal substances’
listed in Chapter I of Annex B of Directive 70/524/EEC. In the current application authorisation under
article 4 (1) of the Regulation (EC) No 1831/2003 is sought for ducks. Monteban® G100 consists of
10% (w/w) of narasin (active substance), rice hulls, mineral oil and verxite. The Applicant suggested a
concentration of narasin in feedingstuffs ranging from 60 to 70 mg/kg. Furthermore, the Applicant
suggests maximum residue limits (MRLs) 50 lg/kg for all relevant duck tissues.
For the quantiﬁcation of narasin in the feed additive, premixtures and feedingstuffs, the Applicant
submitted two single-laboratory validated and further veriﬁed methods based on EN ISO 14183 using
high-performance liquid chromatography with post-column derivatisation coupled to spectrophotometric
detection (HPLC-PCD-UV-Vis). Based on the performance characteristics provided, the EURL recommends
for ofﬁcial control the HPLC-PCD-UV-Vis method for the quantiﬁcation of narasin in the feed additive and
the EN ISO 14183 for the quantiﬁcation of narasin in feedingstuffs.
For the quantiﬁcation of narasin in tissues, the Applicant submitted a single laboratory validated (in
chicken tissues) and further veriﬁed (in a duck tissue) method based on RP-HPLC coupled to a triple
quadrupole mass spectrometer (MS/MS) in electrospray ionisation (ESI) mode using matrix matched
standards, similar to the one developed and validated by the European Union Reference Laboratory for
Pharmacologically Active Substances (BVL). The satisfactory performance characteristics provided by
the Applicant for the tissues of concern demonstrate that (i) the method proposed by the Applicant is
equivalent to the BVL method, (ii) the Applicant method is also applicable to kidney and skin/fat
tissues and (iii) the Applicant method is also applicable to duck tissues. Based on the performance
characteristics presented, the EURL recommends for ofﬁcial control the single laboratory validated and
further veriﬁed RP-HPLC–MS/MS method proposed by the Applicant to enforce the narasin MRLs in the
relevant tissues.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005) is not
considered necessary.
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